Medical management of vascular anomalies.
We have entered an exciting era in the care of patients with vascular anomalies. These disorders require multidisciplinary care and coordination and dedicated centers have emerged to address this need. Vascular tumors have been treated with medical therapies for many years, while malformations have been historically treated with endovascular and operative procedures. The recent serendipitous discoveries of propranolol and sirolimus for vascular anomalies have revolutionized this field. In particular, sirolimus responses are challenging the dogma that vascular malformations are not biologically active. While initially explored for lymphatic anomalies, sirolimus is now being used broadly throughout the spectrum of vascular anomalies. Whether medical therapies are reserved for refractory patients or used first line is currently dependent on the experience and availability of alternative therapies at each institution. On the horizon, we anticipate new drugs targeting genes and pathways involved in vascular anomalies to be developed. Also, combinations of medications and protocols combining medical and procedural approaches are in development for refractory patients.
Boston Children's Hospital, Boston, Massachusetts, USA. cameron.trenor@childrens.harvard.edu.
Cameron C
CC
Trenor
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D000066491:Clinical Decision-Making; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D000068677:Sildenafil Citrate / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D054079:Vascular Malformations / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists; D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D000068258:Bevacizumab; D013792:Thalidomide; D007372:Interferons; D011433:Propranolol; D000068677:Sildenafil Citrate; D020123:Sirolimus